메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류

추천
검색

논문 기본 정보

자료유형
학술저널
저자정보
Koh Seong-Joon (Department of Internal Medicine Liver Research Institute Seoul National University College of Medicine Seoul Korea.) 홍성노 (삼성서울병원) 박수경 (성균관대학교 의과대학 강북삼성병원 소화기내과) 예병덕 (울산대학교) 김경옥 (영남대학교) 신정은 (단국대학교) 윤용식 (서울아산병원) Lee Hong Sub (Department of Internal Medicine Inje University Busan Paik Hospital Inje University College of Medicine Busan Korea) 정성훈 (가톨릭대학교) Choi Miyoung (National Evidence-Based Healthcare Collaborating Agency Seoul Korea) 나수영 (가톨릭대학교 의과대학 인천성모병원 내과) 최창환 (중앙대학교) 김주성 (서울대학교)
저널정보
대한장연구학회 Intestinal research Intestinal research Vol.21 No.1
발행연도
2023.1
수록면
43 - 60 (18page)
DOI
10.5217/ir.2022.00029

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색

초록· 키워드

오류제보하기
Crohn’s disease (CD) is a relapsing and progressive condition characterized by diarrhea, abdominal pain, weight loss, and hematochezia that results in serious complications such as perforations, fistulas, and abscesses. Various medications, interventions, and surgical treatments have been used to treat CD. The Korean guidelines for CD management were distributed in 2012 and revised in 2017 by the Inflammatory Bowel Disease (IBD) Research Group of the Korean Association for the Study of Intestinal Diseases. Substantial progress in mucosal immunologic research has elucidated the pathophysiology of IBD, leading to development of biological agents for treatment of CD. The first developed biologic agent, tumor necrosis factor-α agents, were shown to be efficacious in CD, heralding a new era in management of CD. Subsequently, vedolizumab, a monoclonal antibody against integrin α4β7, and ustekinumab, a human monoclonal antibody that inhibits the common p40 subunit of interleukin-12 and interleukin-23, were both approved for clinical use and are efficacious and safe for both induction and maintenance of remission in moderate-to-severe CD patients. Moreover, a recent study showed the non-inferiority of CT-P13, an infliximab biosimilar, compared with infliximab in CD patients. The third Korean guidelines for CD management provide updated information regarding treatment of moderate-to-severe CD patients with biologic agents.

목차

등록된 정보가 없습니다.

참고문헌 (0)

참고문헌 신청

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

이 논문의 저자 정보

최근 본 자료

전체보기

댓글(0)

0